Contents

8 Hepatitis B

References

  1. Van Damme, Ward, Shouval D, et al. 2013. Hepatitis B vaccines. In: Plotkin SA, Orenstein WA, Offit PA (eds). Vaccines (6th edition): Elsevier Saunders.
  2. McMahon BJ, Alward WLM, Hall DB, et al. 1985. Acute hepatitis B virus infection: relation of age to the clinical expression of disease and subsequent development of the carrier state. Journal of Infectious Diseases 151(4): 599–603.
  3. Bond WW, Favero MS, Petersen NJ, et al. 1981. Survival of hepatitis B virus after drying and storage for one week. The Lancet 317(8219): 550–1.
  4. Alter HJ. 2012. To have B or not to have B: vaccine and the potential eradication of hepatitis B. Journal of Hepatology 57(4): 715–7.
  5. Ott JJ, Stevens GA, Groeger J, et al. 2012. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine 30(12): 2212–19.
  6. Centers for Disease Control and Prevention. 2014. Hepatitis B. CDC Health Information for International Travel 2014. New York, NY: Oxford University Press.
  7. Milne A. 1985. Prevalence of hepatitis B infections in a multiracial New Zealand community. New Zealand Medical Journal 98(782): 529–32.
  8. Moyes CD, Milne A. 1986. Hepatitis B markers in 14–15 year olds in the Bay of Plenty. New Zealand Medical Journal 99(809): 662–4.
  9. Stehr-Green, Briasco C, Baker M, et al. 1992. How well are we protecting our children?: an immunisation coverage survey in Hawke’s Bay. New Zealand Medical Journal 105(938): 277–9.
  10. Ramadas D, Moyes CD, Ramadas G. 1992. Immunisation status of children in the Eastern Bay of Plenty. New Zealand Medical Journal 105(942): 378–9.
  11. Rainger W, Solomon N, Jones N, et al. 1998. Immunisation coverage and risk factors for immunisation failure in Auckland and Northland. New Zealand Public Health Report 5(7): 49–51.
  12. Institute of Environmental Science and Research Ltd. 2013. Notifiable and Other Diseases in New Zealand: Annual report 2012. URL: https://surv.esr.cri.nz/PDF_surveillance/AnnualRpt/AnnualSurv/2012/2012AnnualSurvRpt.pdf (accessed 19 August 2013).
  13. Robinson T, Bullen C, Humphries W, et al. 2005. The New Zealand Hepatitis B Screening Programme: screening coverage and prevalence of chronic hepatitis B infection. New Zealand Medical Journal 118(1211): U1345.
  14. Mann J, Roberts M. 2011. Modelling the epidemiology of hepatitis B in New Zealand. Journal of Theoretical Biology 269(1): 266–72.
  15. Addidle M. 2011. Impact of universal hepatitis B vaccination on antenatal hepatitis B prevalence in the Midlands region of the North Island, New Zealand. New Zealand Medical Journal 124(1332). URL: http://journal.nzma.org.nz/journal/124-1332/4603/content.pdf (accessed 6 December 2013).
  16. Hepatitis Foundation of New Zealand. Hepatitis B Algorithm. URL: www.hepfoundation.org.nz (accessed 25 September 2013).
  17. Lee C, Gong Y, Brok J, et al. 2006. Effect of hepatitis B immunisation in newborn infants of mothers positive for hepatitis B surface antigen: systematic review and meta-analysis. British Medical Journal 332(7537): 328–36.
  18. oyes CD, Milne A, Waldon J. 1990. Very low dose hepatitis B vaccination in the newborn: anamnestic response to vaccine at four years. Journal of Medical Virology 30(3): 216–18.
  19. West DJ, Calandra GB. 1996. Vaccine induced immunologic memory for hepatitis B surface antigen: implications for policy on booster vaccination. Vaccine 14(11): 1019–27.
  20. Su WJ, Liu CC, Liu DP, et al. 2012. Effect of age on the incidence of acute hepatitis B after 25 years of a universal hepatitis B immunization program in Taiwan. Journal of Infectious Diseases 205(5): 757–62.
  21. McMahon BJ, Bulkow LR, Singleton RJ, et al. 2011. Elimination of hepatocellular carcinoma and acute hepatitis B in children 25 years after a hepatitis B newborn and catch-up immunization program. Hepatology 54(3): 801–7.
  22. Perz JF, Elm JL Jr, Fiore AE, et al. 2006. Near elimination of hepatitis B virus infections among Hawaii elementary school children after universal infant hepatitis B vaccination. Pediatrics 118(4): 1403–8.
  23. Chen D-S. 2009. Hepatitis B vaccination: the key towards elimination and eradication of hepatitis B. Journal of Hepatology 50(4): 805–16.
  24. Lee CL, Ko YC. 1997. Hepatitis B vaccination and hepatocellular carcinoma in Taiwan. Pediatrics 99(3): 351–3.
  25. Chang M-H. 2011. Hepatitis B virus and cancer prevention. In: Senn H-J, Otto F (eds). Clinical Cancer Prevention: Berlin & Heidelberg: Springer.
  26. Ministry of Health. 2012. National Guidelines for Vaccine Storage and Distribution. URL: www.health.govt.nz/publication/national-guidelines-vaccine-storage-and-distribution-2012
  27. Marsano LS, West DJ, Chan I, et al. 1998. A two-dose hepatitis B vaccine regimen: proof of priming and memory responses in young adults. Vaccine 16(6): 624–9.
  28. Marchou B, Excler JL, Bourderioux C, et al. 1995. A three-week hepatitis B vaccination schedule provides rapid and persistent protective immunity: a multicenter, randomized trial comparing accelerated and classic vaccination schedules. Journal of Infectious Diseases 172(1): 256–60.
  29. American Academy of Pediatrics. 2012. Hepatitis B. In: Pickering LK, Baker CJ, Kimberlin DW, et al (eds). Red Book: 2012 report of the Committee on Infectious Diseases (29th edition). Elk Grove Village, IL: American Academy of Pediatrics.
  30. Committee on Infectious Diseases. 1994. Update on timing of hepatitis B vaccination for premature infants and for children with lapsed immunisation. Pediatrics 94(3): 403–4.
  31. Ministry of Health. 2012. Communicable Disease Control Manual 2012. URL: www.health.govt.nz/publication/communicable-disease-control-manual-2012
  32. Lehrnbecher T, Schubert R, Allwinn R, et al. 2011. Revaccination of children after completion of standard chemotherapy for acute lymphoblastic leukaemia: a pilot study comparing different schedules. British Journal of Haematology 152(6): 754–7.
  33. Agostini CV, Boccazzi A, Pontari S, et al. 2011. Inadequate seroconversion rates in celiac disease after 3 doses of hepatitis B vaccine, administered at 3, 5 and 11 months of life. Journal of Pediatric Infectious Diseases 6(3): 173–6.
  34. Flynn PM, Cunningham CK, Rudy B, et al. 2011. Hepatitis B vaccination in HIV-infected youth: a randomized trial of three regimens. Journal of Acquired Immune Deficiency Syndromes 56(4): 325–32.
  35. Landrum ML, Hullsiek KH, Chun HM, et al. 2011. The timing of hepatitis B virus (HBV) immunization relative to human immunodeficiency virus (HIV) diagnosis and the risk of HBV infection following HIV diagnosis. American Journal of Epidemiology 173(1): 84–93.
  36. Launay O, van der Vliet D, Rosenberg AR, et al. 2011. Safety and immunogenicity of 4 intramuscular double doses and 4 intradermal low doses vs standard hepatitis B vaccine regimen in adults with HIV-1: a randomized controlled trial. Journal of the American Medical Association 305(14): 1432–40.
  37. Overton ET, Kang M, Peters MG, et al. 2010. Immune response to hepatitis B vaccine in HIV-infected subjects using granulocyte-macrophage colony-stimulating factor (GM-CSF) as a vaccine adjuvant: ACTG study 5220. Vaccine 28(34): 5597–5604.
  38. Peters PJ, Marston BJ. 2012. Preventing deaths in persons with HIV/hepatitis B virus coinfection: a call to accelerate prevention and treatment efforts. Journal of Infectious Diseases 205(2): 166–8.
  39. Beran J, Hobzova JL, Wertzova V, et al. 2010. Safety and immunogenicity of an investigational adjuvanted hepatitis B vaccine (HB-AS02V) in healthy adults. Human Vaccines 6(7): 578–84.
  40. Karaman S, Vural S, Yildirmak Y, et al. 2011. Assessment of hepatitis B immunization status after antineoplastic therapy in children with cancer. Annals of Saudi Medicine 31(6): 573–6.
  41. European Consensus Group on Hepatitis B Immunity. 2000. Are booster immunisations needed for lifelong hepatitis B immunity? The Lancet 355(9203): 561–5.
  42. Runnegar N, Playford G. 2005. Intradermal hepatitis B vaccination in healthcare workers who fail to respond to intramuscular vaccination: a retrospective review of response. Paper presented at the Control of Communicable Diseases Conference 2005, Sydney, Australia.
  43. Schousboe M. 2002. Intradermal hepatitis B vaccination of healthcare workers previously unresponsive to intramuscular hepatitis B vaccination. Paper presented at the Immunisation Conference 2002, Christchurch, New Zealand.
  44. De Vries-Sluijis T, Hansen B, van Doornum GJ, et al. 2008. A prospective open study of the efficacy of high-dose recombinant hepatitis B re challenge vaccination in HIV-infected patients. Journal of Infectious Diseases 197(2): 292–4.
  45. Chow KM, Law MC, Leung C, et al. 2006. Antibody response to hepatitis B vaccine in end stage renal disease patients. Nephron 103(3): c89–93.
  46. Cardell K, Akerlind B, Sallberg M, et al. 2008. Excellent response to a double dose of the combined hepatitis A and B vaccine in previous non-responders to hepatitis B vaccine. Journal of Infectious Diseases 198(3): 299–304.
  47. Institute of Medicine. 2012. Adverse Effects of Vaccines: Evidence and causality Washington DC: The National Academies Press.
  48. Expanded Programme on Immunization (EPI). 1997. Lack of evidence that hepatitis B vaccine causes multiple sclerosis. Weekly Epidemiological Record 72(21): 149–52.
  49. Sadovnick AD, Scheifele DW. 2000. School-based hepatitis B vaccination programme and adolescent multiple sclerosis. The Lancet 355(9203): 549–50.
  50. Report of the working group on the possible relationship between hepatitis B vaccination and the chronic fatigue syndrome. 1993. Canadian Communicable Disease Report 19(4): 25–8.
  51. Wise R, Kiminyo K, Salive M. 1997. Hair loss after routine immunizations. Journal of the American Medical Association 278(14): 1176–8.
  52. Ronchi F, Cecchi P, Falcioni F, et al. 1998. Thrombocytopenic purpura as an adverse reaction to recombinant hepatitis B vaccine. Archives of Disease in Childhood 78(3): 273–4.
  53. McMahon BJ, Helminiak C, Wainwright RB, et al. 1992. Frequency of adverse reactions to hepatitis B vaccine in 43,618 persons. American Journal of Medicine 92(3): 254–6.
  54. Fisher MA, Eklund SA, James SA, et al. 2001. Adverse events associated with hepatitis B vaccine in US children less than six years of age, 1993 and 1994. Annals of Epidemiology 11(1): 13–21.
  55. Ni YH, Chang MH, Wu JF, et al. 2012. Minimization of hepatitis B infection by a 25-year universal vaccination program. Journal of Hepatology 57(4): 730–5.
  56. Romanò L, Paladini S, Van Damme P, et al. 2011. The worldwide impact of vaccination on the control and protection of viral hepatitis B. Digestive and Liver Disease 43(Suppl 1): S2–7.
  57. Heymann DL (ed). 2008. Control of Communicable Diseases Manual (19th edition). Washington DC: American Public Health Association.